Regulations.gov document
Attachment 1 - Approved Drug Products with Therapeutic Equivalence Evaluations of RLD…
Supporting & Related Material · FDA-2022-P-1938 · posted Aug 18, 2022
Key facts
| Document ID | FDA-2022-P-1938-0003 |
|---|---|
| Title | Attachment 1 - Approved Drug Products with Therapeutic Equivalence Evaluations of RLD, Electronic Orange Book listing, accessed Sep 19, 2020 RE Suitability Petition from Suven Pharmaceuticals Limited |
| Document type | Supporting & Related Material |
| Subtype | Background Material |
| Agency | FDA |
| Docket | FDA-2022-P-1938 |
| Posted | Aug 18, 2022 |
At a glance
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: